Semaglutide Recall: Wegovy Injection Pens
Announced 2026-01-07 · FDA
The FDA recall covers Wegovy (semaglutide) Injection pens, 0.5 mg/0.5 mL, 4 single-dose prefilled pens, manufactured by Novo Nordisk A/S and distributed nationwide. The recall is due to the presence of particulate matter, specifically hair, in a prefilled syringe. Affected lots are Lot RZFHD52 and RZFHW93, with expiration date 10/31/2026.
| Brand | Novo Nordisk Inc. |
|---|---|
| Product | Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4505-14 |
| Reason | Presence of Particulate Matter: Hair was found in a prefilled syringe |
| Severity | moderate |
| Units affected | N/A |
| Distribution | Nationwide within the United States. |
| Agency | FDA |
| Recall / campaign no. | Lot #: RZFHD52, RZFHW93; Exp Date 10/31/2026 |
WHAT YOU SHOULD DO
- Do not use Wegovy injection pens from the affected lots (RZFHD52 or RZFHW93).
- Check the lot number on your package to confirm if it is affected.
- Contact your healthcare provider or Novo Nordisk for replacement guidance and instructions on returning the product.
- If you have used the product or have concerns, report them to your healthcare provider.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.